Parsey Merdad's Form 4 filing
Gilead Sciences, Inc. (GILD) · filed Mar 2, 2023
- Accession no.
- 0001127602-23-008491
- Filed
- Mar 2, 2023
- Trade date
- Mar 1, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $1.04M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Parsey MerdadCIK 0001792150 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | Common Stock | SSaleDisposed | −12,984 | $79.96F2 | −$1,038,200.64 | 70,130 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Sale prices reported for the transactions reported here range from $79.60 to $80.34. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Referenced by the price of 1 transaction in Table I.